HC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Maintains $8 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Sean Lee has reiterated a 'Buy' rating on Plus Therapeutics (NASDAQ:PSTV) and maintained an $8 price target.
August 15, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Plus Therapeutics' stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $8.
The reiteration of the 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Plus Therapeutics. This could potentially attract investors and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100